BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36567009)

  • 21. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer.
    Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA
    Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
    Osborne JE; Hutchinson PE
    Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.
    Tokar EJ; Webber MM
    Clin Exp Metastasis; 2005; 22(3):275-84. PubMed ID: 16158255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1993 May; 132(5):1952-60. PubMed ID: 7682937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
    Hedlund TE; Moffatt KA; Miller GJ
    Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
    Miller GJ; Stapleton GE; Ferrara JA; Lucia MS; Pfister S; Hedlund TE; Upadhya P
    Cancer Res; 1992 Feb; 52(3):515-20. PubMed ID: 1370648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Vitamin D3 metabolism in prostate cancer.
    Lou YR; Qiao S; Talonpoika R; Syvälä H; Tuohimaa P
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):317-25. PubMed ID: 15663995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.
    Tokar EJ; Webber MM
    Clin Exp Metastasis; 2005; 22(3):265-73. PubMed ID: 16158254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
    Bao BY; Hu YC; Ting HJ; Lee YF
    Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells.
    Leman ES; DeMiguel F; Gao AC; Getzenberg RH
    J Urol; 2003 Jul; 170(1):235-40. PubMed ID: 12796696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
    Flores O; Burnstein KL
    Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of HBL100 human breast epithelial cells to vitamin D action.
    Agadir A; Lazzaro G; Zheng Y; Zhang XK; Mehta R
    Carcinogenesis; 1999 Apr; 20(4):577-82. PubMed ID: 10223184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
    Swamy N; Persons KS; Chen TC; Ray R
    J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands.
    Ahonen MH; Zhuang YH; Aine R; Ylikomi T; Tuohimaa P
    Int J Cancer; 2000 Apr; 86(1):40-6. PubMed ID: 10728592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling.
    Blasiak J; Chojnacki J; Pawlowska E; Jablkowska A; Chojnacki C
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells.
    Leman ES; Getzenberg RH
    J Cell Biochem; 2003 Feb; 88(3):609-22. PubMed ID: 12532336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
    Sepulveda VA; Weigel NL; Falzon M
    Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-talk of Aryl Hydrocarbon Receptor (AHR)- and Vitamin D Receptor (VDR)-signaling in Human Keratinocytes.
    Christofi C; Lamnis L; Stark A; Palm H; Römer K; Vogt T; Reichrath J
    Anticancer Res; 2022 Oct; 42(10):5049-5067. PubMed ID: 36191995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.